Track topics on Twitter Track topics that are important to you
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today.
We are pleased to share a blog post from Professor Meir Pugatch, IPKM Professor of Valorisation, Entrepreneurship and Management at the University of Maastricht and Managing Director of Pugatch Consilium, a boutique research consultancy.
In a world of global investment flows, securing a larger portion of the $150 billion invested per year by the research-based biopharmaceutical industry is anyone’s game. The 2017 results of the annual Biopharmaceutical Competitiveness & Investment (BCI) Survey, previewed at the International BIO Convention in San Diego in June, reveal that biopharmaceutical competitiveness turns on the policy conditions that countries decide to put in place. A number of BRICs and APAC countries punch below their weight in competitiveness because of detrimental policies for biopharmaceutical innovators. In contrast, the outstanding feature among those rated as most competitive in the 2017 BCI is a clear, systematic, and ongoing commitment to a policy environment that supports biopharmaceutical innovation. This is true for “newcomer” markets rated at the top – like Singapore, Israel, and Taiwan – as well as “mature” markets like Switzerland and the U.S.NEXT ARTICLE
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...